Khorana risk score

Estimate risk of chemotherapy-associated thrombosis

The global unit selector only affects unanswered questions
1.Site of Cancer?
2.Pre-Chemotherapy Platelet Count ≥350 x 10⁹/L
3.Hemoglobin Level <100 g/L or Red Cell Growth Factor Use
4.Pre-Chemotherapy Leukocyte Count >11 X 10⁹
5.BMI ≥35 kg/m²
Created by

1. Site of Cancer?

Created by
0/5 completed

About this Calculator

This risk model for chemotherapy-associated thrombosis was developed and validated using an observational cohort of cancer patients initiating chemotherapy within the United States. Inclusion criteria were patients starting a new chemotherapy regimen, and those who were expected to complete at least 4 cycles. Only venous thromboembolism events were included, and were diagnosed by the treating clinician.

Using baseline clinical and biochemical characteristics in patients starting chemotherapy, a risk score for chemotherapy-associated VTE events classifies patients into low, intermediate, and high risk groups.

Previous thromboprophylaxis trials in cancer patients receiving chemotherapy have not demonstrated a significant benefit. Identifying cancer patients at high risk of VTE may help guide clinican decision-making. Prospective trials evaluating the clinical applicability of this score, and its role in patient selection for thromboprophylaxis have not yet been conducted.

References

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW.

Development and validation of a predictive model for chemotherapy-associated thrombosis.

Blood 2008 May 15, 111 (10): 4902-7

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.